Equels Thomas K
CEO & President
Equels Thomas K has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company, with disclosures dating back to 2026. 6 of those filings fall inside the rolling window. Most recent filing: Oct 23, 2026.
On the most recent filing, Equels Thomas K is listed as CEO & President at AIM ImmunoTech Inc. Inside the rolling window, Equels Thomas K reported 5 open-market purchases totaling $19K in AIM and no open-market sales. The largest disclosed transaction in the window is a purchase of 31,250 AIM shares on Oct 22, 2026, worth $5K.
Companies traded
Other insiders at AIM
Insider Buying
$19K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Equels Thomas K made?
Equels Thomas K has filed 6 SEC Form 4 filings (6 transaction rows) across 1 company since 2026.
Which companies does Equels Thomas K trade?
Equels Thomas K has filed SEC Form 4 disclosures for 1 company, including AIM.
When was Equels Thomas K's most recent SEC Form 4 filing?
Equels Thomas K's most recent SEC Form 4 filing on Tracefour is dated Oct 23, 2026.
What is Equels Thomas K's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Equels Thomas K is listed as CEO & President.
What is Equels Thomas K's total buy and sell value in the current window?
Inside the rolling retention window, Equels Thomas K bought $19K and sold $0 based on SEC Form 4 filings.
What was Equels Thomas K's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 31,250 AIM shares on 2026-10-22, worth $5K, per SEC Form 4 filings.